Anifrolumab significantly reduced disease activity as measured by several SLE composite endpoints and improved symptoms of lupus.
A new analysis of data from a phase II clinical study of Edratide support the need for additional longer term studies in lupus.
Treat-to-Target is a treatment approach that has been used successfully in other diseases, including rheumatoid arthritis and diabetes. An international group of lupus experts has developed a set of recommendations for using this principle in lupus.
Study examines the effects of the antimalarial drug, hydroxycloroquine, on antiphospholipid antibodies that are responsible for pregnancy complications in women with lupus and antiphospholipid syndrome.
Lupus Foundation of America medical director Dr. Joan Merrill discusses a recently completed a study that may help to improve the design for future lupus clinical trials and secure approval of new safe and more tolerable treatments for lupus.
Dr. Miriam Kaufman discusses a smartphone app that helps adolescents make the transition from pediatric to adult lupus care.
Dr. Hermine Brunner of the Cincinnati Children's Hospital discusses her research on health-related quality of life in children and adolescents with lupus.
Dr. Gary Gilkeson of the Medical University of South Carolina discusses his Lupus Foundation of America funded study on the potential use of human mesenchymal stem cells as a therapy for lupus.